Sort   by:  
 Page size 
UnknownMultisystem Inflammatory Syndrome in U.S. Children and Adolescents.

Background

Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome.

Methods

We cond...
S-EPMC7346765 | biostudies-literature
UnknownMultisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.

Background

The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.

Methods

We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 5...
S-EPMC8220972 | biostudies-literature
UnknownResearching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design.

Importance

The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in child...
S-EPMC11075869 | biostudies-literature
UnknownCharacterizing Long COVID in Children and Adolescents.

Importance

Most research to understand postacute sequelae of SARS-CoV-2 infection (PASC), or long COVID, has focused on adults, with less known about this complex condition in children. Research is needed to characterize pediatric PASC to enable studies of underlying mechanisms that will gui...
S-EPMC11339705 | biostudies-literature
UnknownNeurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome.

Importance

Coronavirus disease 2019 (COVID-19) affects the nervous system in adult patients. The spectrum of neurologic involvement in children and adolescents is unclear.

Objective

To understand the range and severity of neurologic involvement among children and adolescents associate...
S-EPMC7936352 | biostudies-literature
UnknownProgression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age.

Purpose

To report the prevalence of myopia and high myopia in children <6 years of age born preterm with birth weights <1251 g who developed high-risk prethreshold retinopathy of prematurity and who participated in the Early Treatment for Retinopathy of Prematurity trial.

Methods

Surv...
S-EPMC3725578 | biostudies-literature
UnknownAerosol precautions and airway complications: a national prospective multicentre cohort study.
The perceived risk of transmission of aerosolised viral particles from patients to airway practitioners during the COVID-19 pandemic led to the widespread use of aerosol precautions, including personal protective equipment and modifications to anaesthetic technique. The risk of these aerosol precaut...
S-EPMC10087829 | biostudies-literature
UnknownFactors associated with D-dimer levels in HIV-infected individuals.

Background

Higher plasma D-dimer levels are strong predictors of mortality in HIV+ individuals. The factors associated with D-dimer levels during HIV infection, however, remain poorly understood.

Methods

In this cross-sectional study, participants in three randomized controlled trials...
S-EPMC3953205 | biostudies-literature
UnknownPredominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.

Purpose

To describe predominantly persistent intraretinal fluid (PP-IRF) and its association with visual acuity (VA) and retinal anatomic findings at long-term follow-up in eyes treated with pro re nata (PRN) ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Des...

S-EPMC10282893 | biostudies-literature
UnknownRanibizumab and bevacizumab for neovascular age-related macular degeneration.

Background

Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.

Methods

In a multicenter, single-bl...
S-EPMC3157322 | biostudies-literature
Sort   by:  
 Page size